Loading...
 
Toggle Health Problems and D

Lung cancer treated by Vitamin D (1200 IU early stage) – RCT July 2018

Vitamin D supplementation and survival of patients with non-small-cell lung cancer: A randomized, double-blind, placebo-controlled trial.

Clin Cancer Res. 2018 Jul 17. pii: clincanres.0483.2018. doi: 10.1158/1078-0432.CCR-18-0483. [Epub ahead of print]

VitaminDWiki

1200 IU for 8 years
Relapse-Free-Survival for those starting with < 20 ng of vitamin D

Image
         years
It is amazing that such a small amount of Vitamin D would help.
Suspect that the Japanese patients were very light-weight
Would need larger doses for standard-weight adults
Larger doses would likely also provide more benefits

Releapse-Free-Survival vs genes (not Vitamin D)

Image
         years


Vitamin D both prevents and treats many cancers
Cancer category starts with the following


Cancers get less Vitamin D when there is a poor Vitamin D Receptor

PDF is available free at Sci-Hub  10.1158/1078-0432.CCR-18-0483

Akiba T1, Morikawa T2, Odaka M2, Nakada T2, Kamiya N3, Yamashita M2, Yabe M2, Inagaki T2, Asano H2, Mori S2, Tsukamoto Y2, Urashima M4.
1 Thoracic Surgery, Jikei University School of Medicine University Hospital.
2 Thoracic Surgery, Tokyo Jikei University of Medicine.
3 Thoracic Surgery, Kitasato University Kitasato institute hospital.
4 Molecular Epidemiology, Jikei University School of Medicine urashima at jikei.ac.jp.

Higher serum 25-hydroxyvitamin D (25(OH)D) levels are reportedly associated with better survival in early-stage non-small-cell lung cancer (NSCLC). Therefore, whether vitamin D supplementation can improve the prognosis of NSCLC patients was examined (UMIN000001869). &#10; Experimental

Design: A randomized, double-blind trial comparing vitamin D supplements (1,200 IU/day) with placebo for 1 year after operation was conducted. The primary and secondary outcomes were relapse-free survival (RFS) and overall survival (OS), respectively. Pre-specified subgroup analyses were performed with stratification by stage (early vs. advanced), pathology (adenocarcinoma vs. others), and 25(OH)D levels (<20 ng/ml vs. high, ≥20 ng/ml). Polymorphisms of vitamin D receptor (VDR) and vitamin D binding protein (DBP) and survival were also examined. &#10;

Results: NSCLC patients (n=155) were randomly assigned to receive vitamin D (n=77) or placebo (n=78) and followed for a median of 3.3 years. Relapse and death occurred in 40 (28%) and 24 (17%) patients, respectively. In the total study population, no significant difference in either RFS or OS was seen with vitamin D compared to the placebo group.
However, by restricting the analysis to the subgroup with early-stage adenocarcinoma with low 25(OH)D, the vitamin D group showed significantly better

  • 5-year RFS (86% vs. 58%, P=0.04) and
  • OS (92% vs. 56%, P=0.02)

than the placebo group. Among the examined polymorphisms, DBP1 (rs7041) TT and CDX2 (rs11568820) AA/AG genotypes were markers of better prognosis, even with multivariate adjustment. &#10;
Conclusions: In NSCLC patients, vitamin D supplementation may improve survival of early-stage lung adenocarcinoma patients with lower 25(OH)D levels.


Created by admin. Last Modification: Tuesday September 4, 2018 15:13:59 GMT-0000 by admin. (Version 10)

Attached files

ID Name Comment Uploaded Size Downloads
10482 LC relapse free survival vs gene.jpg admin 04 Sep, 2018 16.12 Kb 701
10481 LC relapse free survival.jpg admin 04 Sep, 2018 13.36 Kb 656